Will pirtobrutinib be reimbursed by medical insurance?

Pirtobrutinib is a new type of BTK inhibitor, mainly used to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B cell-related diseases. The drug received accelerated approval from the U.S. FDA in January 2023, but it has not yet been launched in China and has not been included in the national medical insurance catalog. Patients cannot obtain the drug through medical insurance reimbursement.

Since Pitobrutinib has not yet been launched in China, patients have difficulty purchasing the drug in China. Currently, there are two types of overseas original drugs: European version and American version, with the latest price being about 100,000 yuan. In addition, the Ministry of Health of Laos has approved the generic version of pitobrutinib produced by Lucius Pharmaceuticals, with a specification of 50mg*30 tablets, and the latest price is less than 3,000 yuan. However, patients should be cautious when choosing to purchase medicines to ensure they are of reliable quality and source.

For drugs that are not yet on the market, patients can obtain them through legal overseas drug purchase channels, but they need to pay attention to relevant policies and legal regulations. Before using this drug, it is recommended that patients consult a professional doctor to understand the indications, usage and dosage of the drug, and possible side effects. At the same time, patients should pay close attention to the dynamics of the domestic pharmaceutical market to keep abreast of the launch and medical insurance inclusion of pitobrutinib.

In short, although pitobrutinib has potential in treating certain B cell-related diseases, it is not currently available in China and is not covered by medical insurance reimbursement. When considering using this drug, patients should weigh factors such as the drug's efficacy, price, and access, and make decisions under the guidance of a professional doctor.

Reference materials:https://go.drugbank.com/drugs/DB17472